SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-16-132670
Filing Date
2016-07-14
Accepted
2016-07-14 14:29:51
Documents
2
Period of Report
2016-06-08

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 6396
2 POA DOCUMENT poa.txt EX-24.3_666754 3286
  Complete submission text file 0001209191-16-132670.txt   11103
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Issuer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121
Business Address
Flynn Peter D (Reporting) CIK: 0001586939 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33415 | Film No.: 161767273